BTK and rheumatoid arthritis: The human RA condition is already well developed by the time treatment occurs and is an overlay of beginning and end stage differentiation and inflammatory processes occurring concomitantly and cyclically, which may affect trial time requirements for determining clinical efficacy for BTK inhibitors.